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Educational aims 
·          To review the existing evidence for chest physiotherapy in paediatric PCD 
·          To discuss the differences between PCD and CF pertaining to mucus clearance 
·          To explore the appropriateness of extrapolating CF research to PCD chest 
physiotherapy practice 
 
 
Future research directions 
Greater understanding of the physiological differences between PCD and CF will increase 
understanding of how mucociliary clearance is facilitated and when it is impaired. 
Knowledge of the effects and benefits of undertaking ACTs in PCD is needed, but as it 
would be unethical to withhold treatment for a randomised-controlled trial consideration will 
need to be given to study designs. Large PCD specific trials of pharmacological agents such 
DVPXFRO\WLFVDUHDOVRUHTXLUHGWRTXDQWLI\WKHµWUXH¶ULVNVDQGEHQHILWs for this population. 
The potential impact of the European Task Force recommendations on practice, is keenly 
awaited. 
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Abstract 
Primary Ciliary Dyskinesia (PCD) is a rare inherited disease with impaired mucociliary 
clearance.  Airway clearance techniques (ACTs) are commonly recommended for patients 
with PCD to facilitate mucus clearance, despite a lack of evidence in this group.  Current 
physiotherapy practice in PCD is based on evidence extrapolated from the field of Cystic 
Fibrosis (CF).  This paper focuses on the available evidence and outlines challenges in 
extrapolating evidence between the conditions for best clinical practice. 
 
1.1 
PCD 
PCD is a rare, predominantly autosomal recessive condition in which ultra-structure 
abnormalities of ciliated cells cause impaired cilial function (1). Impaired cilial function results 
in changes across the body including situs abnormalities (dextrocardia, situs inversus 
totalis), chronic otitis media, sinusitis, rhinitis, subfertility, and the main focus of this review; 
impaired mucociliary clearance from the lungs (2). Normal ciliary function is essential to clear 
the respiratory tract from particles and organisms and in its absence, neonatal respiratory 
distress, a wet cough and persistent nasal discharge are commonly present. Unlike CF, PCD 
is generally not thought to reduce life expectancy, however in a North American cohort of 
patients >18 years, 38% of patients had respiratory failure (3). Centres diagnosing PCD use 
a range of methods including high speed video microscopy, transmission electron 
microscopy, immunofluorescence microscopy, nasal nitric oxide levels, and genetics which 
all have recognised limitations (4,QWKHDEVHQFHRIDVLQJOH³JROGVWDQGDUG´GLDJQRVWLF
method (5), even an experienced team using combination of diagnostic tools can often find 
inconclusive results making diagnosing PCD challenging (6). 
 
1.2 
Epidemiology 
Prevalence of PCD in children aged 5-14 years to be between 0.33-0.5 per 10,000 across 
Europe (7); lower than the European prevalence of CF (0.74 per 10,000) (8). Variance in 
PCD prevalence rates may be true variance across different populations, illustrated by the 
unusually high prevalence of 4.4 per 10,000 amongst the Bradford Pakistani population (9). 
However, spurious variance may be due to under-diagnosis, with patients mis-diagnosed as 
idiopathic bronchiectasis or asthma in geographical areas with a lower awareness of PCD or 
under-diagnosis where availability of diagnostic services are limited (7). The age of 
diagnosis can vary with a median of 5.3 years across European paediatric centres (7) 
compared to a median 23.5 years, range 1-72 years in an adult specialist centre (10), 
reflecting the challenge of diagnosis. Symptoms of a productive cough, rhinorrhea and otitis 
media can be common amongst healthy children, making the presence of situs inversus key 
in early diagnosis for the 50% patients with this feature of the disease (7). It is anticipated 
that prevalence, diagnostic and clinical data will become more detailed and reliable with the 
development of national and international registries. 
 
1.3 
PCD management 
Links between early diagnosis, lower incidence of bronchiectasis and stable lung function 
have been established for over two decades (11) and later diagnosis has been associated 
with increased frequency of Pseudomonas aeruginosa colonisation and lower baseline lung 
function (FEV1) (10). Once diagnosed, condition specific management can be commenced. A 
survey of paediatric PCD patients in European centres (including Turkey, Israel, Serbia and 
Estonia), conducted between 2007 and 2009, aimed to describe service organisation, 
diagnostic methods, treatment-options and long-term follow up (12). There was greater 
consistency in the methods used to diagnose PCD than the treatments used to subsequently 
manage patients and care seemed to mostly be de-centralised. Diagnostically, 90% had 
access to nasal or bronchial mucosal biopsies for patients suspected to have PCD, whereas 
for PCD management; the prescription of antibiotics for exacerbations was consistent 
(87.6% using routinely) but prophylactic antibiotic use was more varied (58% using 
sometimes). Variance was also seen across nebulised hypertonic saline (45.95% using 
sometimes), inhaled corticosteroids (69% using sometimes) and nebulised rhDNase (41.2% 
using sometimes). ACTs were more consistently recommended with 78% of centres 
prescribing these to all patients and 85% of PCD teams employing an integrated 
physiotherapist. Although the results of this survey were not published until 2012, data 
collection was undertaken in 2009, prior to publication of European Task Force proposals for 
diagnosis and management of children with PCD (5). These recommended specialist-centre 
care (either shared- or full-care), regular airway clearance (physiotherapy and exercise), and 
advised on on antibiotic use (in acute airway infections, managing patients colonised with 
Pseudomonas aeruginosa and prophylaxis), anti-inflammatory strategies, exposure to 
smoke and pollutants and advised against the use of N-acetylcysteine.  These 
recommendations were based on PCD evidence categorised by the task force as low level 
on the BMJ GRADE scoring system (13), evidence extrapolated from CF evidence or on 
expert opinion. 
 
1.4 
Airway Clearance Techniques (ACTs) 
ACTs are a range of interventions which aim to facilitate clearance of mucus from the 
airways. These are typically advised by a physiotherapist across a range of conditions in 
which the normal physiological mucociliary escalator is unable to effectively clear the 
airways of the mucus produced. Physiologically ACTs aim to influence regions of ventilation, 
splint open small airways, access channels of collateral ventilation, optimise and bias airflow, 
manipulate the location of the equal pressure point and oscillate air within the airways. The 
skill and expertise of a physiotherapist involves identification of the barriers to the natural 
mucus clearance in an individual, then selecting and advising on application of appropriate 
ACTs to overcome or address the identified barrier. A benchmarking exercise of English 
Paediatric PCD Centres demonstrated the range of ACTs undertaken in this group including; 
positioning, manual techniques (percussion, vibrations), positive pressure adjuncts, 
breathing techniques, and oscillatory devices. 
 
2.1 
Physiotherapy evidence in PCD 
Systematic review of the paediatric PCD literature in databases Medline, Embase, Cinahl 
and Amed found 375 studies using search terms which included variant terms of PCD and 
physiotherapy or ACTs. Of these 342 were excluded (62 duplications, 28 adult studies, 1 
animal study and 252 which did not actually involve ACTs in PCD. Of the remaining 35 
results, 18 comprised of guidelines, literature reviews, conference summaries or PCD 
overviews which were searched for relevant contents and references. Finally 4 case reports 
mentioned but did not focus upon ACTs, 3 studies focused on quality of life and 1 study had 
a mixed Bronchiectatic population and sub-group analysis was not undertaken. The 4 
remaining publications pertaining to this area comprised of two studies on exercise (14-15), 
a discussion paper (16) and a study which specifically focused on the utility of high 
frequency chest wall oscillation (HFCWO) (17). 
 
2.2 
Evidence for ACTs in PCD 
A randomised cross-over design was used to compare HFCWO with postural drainage 
percussion and vibrations (PDPV) in 12 positions performed by a physiotherapist (17). 
Twenty four paediatric PCD patients received one intervention for 5 days and after a 2-day 
washout period; they received the alternate intervention for 5 days, with patients randomly 
allocated to receive either manual techniques or HFCWO first. Outcomes included lung 
IXQFWLRQDQGSDWLHQW¶VUHSRUWVRIERWKFRPIRUWDQGSHUFHLYHGHIIHFWLYHQHVVRIWKH
interventions. A significant improvement in lung function was seen following both 
interventions, but there were no significant differences when comparing interventions. 
Patients preferred HFCWO, however this finding must be interpreted with caution. Firstly, 
participants were in-patients for the PDPV period but at home for the HFCWO period. 
Hospitalisation can be disruptive and associated with times of active illness and this may 
have negatively biased patients against PDPV. Secondly, the patients may have been 
predisposed to prefer a new novel treatment. The generalisability of these findings may be 
limited as the sample had a much higher proportion of situs inversus totalis (91.7%) than the 
general PCD population. 
 
2.3 
Evidence for exercise in PCD 
PCD consensus statements suggest regular exercise may assist secretion clearance and 
have a positive bronchodilation in PCD (2, 5). Again, there is a paucity of literature with only 
2 studies pertaining to exercise in paediatric patients with PCD identified in the search. One 
VWXG\HYDOXDWHGWKHHIIHFWVRIH[HUFLVHDQGDȝJGRVHRIVDOEXWDPRORQOXQJIXQFWLRQLQ
12 paediatric PCD patients (14). The interventions of 8 minutes on a treadmill and a dose of 
salbutamol were given in succession with a rest period, concluding when Peak expiratory 
flow rate (PEFR) had returned to baseline, used as a washout period. It was reported that 
10/12 participants had a better bronchodilator response to exercise than salbutamol, 
however as spirometry was only measured at the start and end of the assessment and not 
between the exercise and salbutamol, it is impossible to attribute the improvements to 
salbutamol alone. Additionally published data illustrates variable PEFRs during exercise with 
intra-subject increases and decreases from baseline in 8/12 of the group. Without a measure 
of cough frequency or secretion clearance, interpretation of the results becomes more 
equivocal. With 16 fast expiratory manoeuvres (PEFR) undertaken to collect data during the 
intervention, the process of data collection could have caused secretion movement, changes 
in airflow and fatigue. It is hypothesised that changes seen in spirometry and PEFR in this 
study are due to a combination of physiological changes and, importantly, secretion 
clearance. 
 
Another study investigated exercise tolerance in PCD patients (15) using maximal 
cardiopulmonary testing, in 10 paediatric patients with PCD and 8 matched controls. They 
found reduced exercise capacity in the PCD patients compared to control (VO2peak and 
increased VE/VCO2 slope), which reached statistical significance in the 40% of the PCD 
sample who had low lung function (FEV1 <85%). Whilst the sample size was small, the 
clinical value of exercise testing in PCD for both assessment and to guide exercise advice 
can be considered. With physical and psychological benefits of exercise in children it is 
reasonable to recommend exercise to patients with PCD generally. However with an 
absence of evidence of the effects of exercise on mucus clearance, caution should be taken 
when recommending exercise in isolation for airway clearance. 
 
3.1 
Key differences between CF and PCD 
With minimal evidence of the effectiveness of ACTs in PCD, practice is often based on 
evidence extrapolated from research in CF (18). Yet, there are notable differences in the 
pathophysiology, disease trajectory and symptoms of the two conditions (19) and it is 
important to consider differences between the conditions which may influence clinical 
application.  PCD is often likened to CF, which is also an inherited condition in which 
mucociliary clearance is impaired. However in PCD the impairment of mucociliary clearance 
is primary and present from birth whereas in CF the mucocilary clearance impairment is 
secondary, possibly due to inflammation, and may be preserved at least initially (20): many 
patients with CF do not have respiratory symptoms at birth. As newborn screening for CF 
has successfully reduced the age of CF diagnosis to a median of 3 weeks (21), debates over 
whether to prescribe routine ACTs to asymptomatic infants with CF have become more 
common (22). These debates are arguably less relevant to PCD as, with symptoms from 
birth and commonly later diagnosis, commencing regular ACTs at the point of a confirmed or 
suspected diagnosis of PCD should be recommended. 
 
In PCD, unlike CF, no correlation has been found between the most reliable measure of 
airway disease (high-resolution CT) and more routinely used measures (lung function and 
lung clearance index (LCI) (23).  $VURXWLQH&7¶VDUHQRWFRQGXFWHGGXHWRULVNVFRVWVDQG
accessibility this poor correlation makes the clinical identification of early signs of 
deterioration more challenging. LCI is more commonly abnormal than lung function in PCD, 
suggesting abnormalities develop in the distal airways prior to the proximal ones (24).  When 
comparing PCD with CF it is hypothesised that there is a different ratio of proximal to distal 
airway disease with CF patients having a greater severity of proximal airway disease (23). In 
PCD a productive cough is usually present from birth leading families become accustomed 
to its presence and role in clearing secretions. It must be remembered that whilst an 
effective cough clearance mechanism is regularly observed in PCD, peripheral airway 
dysfunction exists preventing mobilisation of mucus from smaller airways (24). 
 
3.2  
Selection of appropriate ACTs 
There are a number of interventions shown to be effective in CF which are widely applicable 
to PCD due to common physiological principles. Normal mucus clearance occurs through a 
combination of ciliary clearance and airflow forces shearing and mobilising mucus. This led 
to the development of Autogenic Drainage (AD) (25), which guides patients through the 
manipulation of lung volumes and airflows to move mucus from smaller to larger airways. 
With the absence of an effective ciliary beat, one of two key components in mucus 
clearance, it is logical to utilise the effects of airflow forces in PCD through the utilisation of 
AD. An alternative breathing-pattern-based ACT used in both PCD and CF, the active cycle 
of breathing technique (ACBT), aims to optimise ventilation by reducing ventilation 
asynchrony and mobilise mucus from smaller to larger airways before expectoration. As 
such, it is reasonable to consider either the ACBT or AD in patients with PCD, and with an 
element of concentration and understanding required, clinicians should advise patients on 
these on an individualised basis (26). 
 
Positive expiratory pressure (PEP) devices in CF care have been shown to increase 
functional residual and total lung capacities (27) and would have similar applicability in PCD 
patients in accessing the channels of collateral ventilation and mobilising peripheral mucus. 
Oscillatory PEP devices cause vibrations of the airway walls, which in CF are used to alter 
mucus rheology and augment mucociliary clearance, in addition to the previously discussed 
benefits of standard PEP. All commercially available oscillatory devices (Acapella®, 
Flutter®, Cornet®, Aerobika®) provide oscillatory frequencies similar to normal cilial beat 
frequency, which is thought optimal for secretion clearance (28). Ciliated cells show 
mechano-sensitivity, and stimulation of cultured cilia from healthy samples showed a 
temporary elevation in frequency ciliary beat and potentially increase mucus clearance (29). 
As ciliary beat is commonly slowed or absent in PCD, it is unclear whether the proposed 
effects of oscillatory devices would have a greater or lesser impact on mucociliary clearance 
in PCD. This is an important area for future investigation and raises the prospect of ACT 
prescription tailored to cilial abnormalities in the future. 
 
3.3  
Optimisation of ACTs 
The position in which patients undertake an ACT can be varied and positioning is commonly 
used alongside other ACTs to target areas of lung and optimise regional ventilation (30). 
Ventilation is usually greatest in the dependant regions of the lung; the lower lobes in sitting, 
the lowermost lung areas in supine and the dependant lung in side lying (31). However 
caution should be taken when applying positioning principles as ventilation is thought to be 
to be highly variable even amongst healthy children (32). The location of bronchiectasis 
within the lung has been found to differ on CT scan of patients with PCD and CF. In CF, the 
distribution of bronchiectasis is seen mainly in the upper lobes, yet in PCD bronchiectasis is 
more commonly seen in the middle and lower lobes (33-35). It has been suggested that the 
relative sparing of the upper lobes in PCD may be due to the gravitational augmentation of 
secretion clearance from these areas (35). Thus clinicians may need to explore positioning 
options for patients with PCD, utilising CT scans to target focal areas and physiological 
based clinical reasoning to tailor ACTs for each individual and optimise their efficacy. 
 
3.4  
Consideration of mucus properties 
In CF, impaired Clí and HCO3í secretion and increased epithelial Na+ absorption result in 
dehydrated mucus, which when compounded by the effects of inflammatory mediators make 
CF mucus understandably challenging to clear. Despite differing pathophysiology, mucus 
from PCD patients has been found to have similar biophysical and transport properties to CF 
mucus (18), with significantly higher interleukin-8 levels in PCD mucus than in CF mucus 
(18,20). Within CF, mucolytic dornase alpha (rhDNAse) and osmotic agents such as 
nebulised hypertonic saline are recommended to assist with mucus clearance (36) and can 
be used as an adjunct to ACTs. 
 
The potential risk of extrapolating evidence between conditions is illustrated by the evidence 
base for rhDNAse. Studies in CF have shown improvements in lung function trajectories and 
rates of exacerbation with rhDNase (36). Yet conversely, a large high quality RCT in adults 
with idiopathic bronchiectasis found an increased frequency of exacerbations and a greater 
rate of decline in lung function with rhDNase compared to placebo (37). Whilst this has led to 
recommendation against the use of rhDNAse in PCD (5) improvements in lung function have 
been found in a small number of PCD patients (38-39) reflecting the continued use of this 
costly and controversial mucolytic in some centres (12). With conflicting evidence from other 
conditions and a small PCD evidence base, larger scale trials are needed within PCD to 
inform and guide practice not only with rhDNAse but with all pharmacological adjuncts to 
ACTs. 
 
3.5  
The impact of undertaking ACTs 
Undertaking daily treatments such as ACTs are time-consuming and can be a considerable 
treatment burden for patients causing psychosocial implications. Within PCD, ACTs can 
serve as a cue that individuals might feel different to their peers and reminders of disease 
(40). Coughing is one of the most visible signs of abnormality in PCD, yet one of the 
essential elements of an effective ACT session. Coughing can be a stigma for patients with 
PCD and some children and young people cough supress to conceal their disease (41).  In 
WKLVVHQVH$&7VFDQEHDµSULYDWH¶HOHPHQWRIVHOI-care. Clinicians and patients need to work 
together to balance the challenges of care with the benefits of maintaining quality of life in 
the future (42). It is hoped that the emergence of a PCD specific quality of life measure will 
help to understand the impact of treatments much more (43). 
 
4.1 
Future research directions 
Greater understanding of the physiological differences between PCD and CF will add to 
understanding of how mucociliary clearance is facilitated and when it is impaired. Whilst it 
would be unethical to withhold ACTs from patients with PCD, randomised-controlled trials of 
their effects, knowledge of the benefits of undertaking daily time-consuming treatments is 
needed. Large PCD specific trials of pharmacological agents such as mucolytics are also 
UHTXLUHGWRTXDQWLI\WKHµWUXH¶ULVNVDQGEHQHILWVIRUWKLVSRSXODWLRQ7KHLPSDFWRI(XURSHDQ
Task Force recommendations on practice, especially in aspects where practice was not in 
line with recommendations is keenly awaited. 
 
4.2 
Conclusion 
In the absence of PCD-specific research, clinical practice must be based on the best 
available evidence and expert opinion.  Knowledge and understanding transposed from 
studies in people with CF have provided the foundation on which PCD care has been 
built.  However, there are fundamental physiological differences between the conditions and 
caution needs to exercised prior to more comprehensive extrapolation.  The lack of research 
in PCD populations is well recognised but it is hoped that the evidence-base will grow. At 
present, consensus supports the recommendation of ACTs to all patients with PCD. 
Exercise is recommended across the general population and should be encouraged in 
SDWLHQWVZLWK3&'KRZHYHULWV¶XWLOLW\DVDQDLUZD\FOHDUDQFHWHFKQLTXHQHHGVIXUWKHU
evaluation. The clinical reasoning of treatments based on sound physiological principles sits 
within the scope of physiotherapy and regular physiotherapy reviews will ensure patients 
with PCD undertake effective ACTs. 
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